4-[(4-Aminophenoxy)methyl]aniline | 70894-11-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-[(4-Aminophenoxy)methyl]aniline
• CAS: 70894-11-0
• 化学式: C₁₃H₁₄N₂O
• mdl: MFCD24392011
• 分子量: 214.267
• InChiKey: VYYVHHWQRAEFOL-UHFFFAOYSA-N

物化性质

• 沸点：
  424.3±25.0 °C(Predicted)
• 密度：
  1.199±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  61.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(4-Aminophenoxy)methyl]aniline 生成 1-Isocyanato-4-[(4-isocyanatophenoxy)methyl]benzene
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• BENZENE DERIVATIVES AND MEDICINAL USE THEREOF
  申请人：Ajinomoto Co., Inc.

  公开号：EP1113000A1

  公开（公告）日：2001-07-04

  The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

  本发明提供了一种 AP-1 活化抑制剂、NF-kappa B 活化抑制剂、炎症细胞因子产生抑制剂、基质金属蛋白酶产生抑制剂、炎症细胞粘附分子表达抑制剂、抗炎剂、抗风湿剂、免疫抑制剂、癌症转移抑制剂、动脉硬化治疗剂和抗病毒剂，其活性成分含有下通式（I）的苯衍生物或其药学上可接受的盐。
• Varnish for photo alignment film and liquid crystal display device
  申请人：Japan Display Inc.

  公开号：US10947345B2

  公开（公告）日：2021-03-16

  According to one embodiment, a varnish for a photo alignment film includes an imidization promotor and a first polyamic acid-based compound in an organic solvent. The first polyamic acid-based compound is a polyamic acid or a polyamic acid ester. The imidization promotor has skeleton containing no primary amino group and no secondary amino group. The first polyamic acid-based compound has terminal skeletons containing no primary amino group.

  根据一个实施方案，用于光配准膜的清漆包括亚胺化促进剂和有机溶剂中的第一种聚胺基酸基化合物。第一种聚酰胺基化合物是聚酰胺酸或聚酰胺酸酯。亚胺化促进剂的骨架不含伯氨基和仲氨基。第一种聚酰胺基化合物具有不含伯氨基的末端骨架。
• Benzene derivatives and Pharmaceutical use thereof
  申请人：Ajinomoto Co., Inc.

  公开号：US20010018441A1

  公开（公告）日：2001-08-30

  The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. 1

  本发明提供了一种AP-1活化抑制剂、NF-kappa B活化抑制剂、炎症细胞因子产生抑制剂、基质金属蛋白酶产生抑制剂、炎症细胞粘附分子表达抑制剂、抗炎剂、抗风湿剂、免疫抑制剂、癌症转移抑制剂、动脉硬化治疗剂和抗病毒剂，其活性成分含有下通式（I）的苯衍生物或其药学上可接受的盐。 1
• Benzene derivatives and pharmaceutical use thereof
  申请人：AJINOMOTO CO., INC

  公开号：US20030166693A1

  公开（公告）日：2003-09-04

  The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. 1

  本发明提供了一种AP-1活化抑制剂、NF-kappa B活化抑制剂、炎症细胞因子产生抑制剂、基质金属蛋白酶产生抑制剂、炎症细胞粘附分子表达抑制剂、抗炎剂、抗风湿剂、免疫抑制剂、癌症转移抑制剂、动脉硬化治疗剂和抗病毒剂，其活性成分含有下通式（I）的苯衍生物或其药学上可接受的盐。 1
• HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies
  作者：Omar D. Lopez、Van N. Nguyen、Denis R. St. Laurent、Makonen Belema、Michael H. Serrano-Wu、Jason T. Goodrich、Fukang Yang、Yuping Qiu、Amy S. Ripka、Peter T. Nower、Lourdes Valera、Mengping Liu、Donald R. O’Boyle、Jin-Hua Sun、Robert A. Fridell、Julie A. Lemm、Min Gao、Andrew C. Good、Nicholas A. Meanwell、Lawrence B. Snyder

  DOI：10.1016/j.bmcl.2012.11.086

  日期：2013.2

  In a recent disclosure,(1) we described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon. That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region. From this effort, the contribution of the core region to the overall topology of the pharmacophore, primarily vector orientation and planarity, was determined, with a set of analogs exhibiting < 10 nM EC50 in a genotype 1b replicon assay. (c) 2012 Elsevier Ltd. All rights reserved.